Nautilus Biotechnology

Historical price data

Nautilus Biotechnology is on a mission to revolutionize biomedicine by unlocking the full complexity of the human proteome, moving beyond the limitations of mass spectrometry. Its core achievement is the development of the Voyager™ Platform, a benchtop system utilizing Iterative Mapping to quantify billions of single protein molecules with high accuracy, sensitivity, and reproducibility. The company's strategy is to establish its technology as a new gold standard in proteomics, initially through an Early Access Program with key research collaborators, with the long-term goal of enabling breakthroughs in drug discovery, precision medicine, and fundamental biological research.

The Voyager™ Platform utilizes proprietary Iterative Mapping technology to enable single-molecule quantification of billions of proteins and proteoforms with high accuracy, sensitivity, and reproducibility on a benchtop instrument.

Nautilus competes directly with mass spectrometry giants (Thermo Fisher, Bruker) and alternative next-gen proteomics platforms (Seer, Quantum-Si). Its differentiation hinges on proving a unique combination of single-molecule analysis, full-proteome scale, and benchtop workflow—a value proposition that must overcome high switching costs and established competitor moats.